Kathryn’s recent experience includes serving on Weil teams representing Illumina in winning a November 2021 jury verdict of willful infringement against BGI in a competitor patent dispute regarding DNA sequencing technologies and AbbVie in pending Hatch-Waxman litigation against Sandoz regarding method of treatment patents for one of its blockbuster drug products, Combigan.
Kathryn previously worked as a research scientist at a medical diagnostics company. She received her J.D. from New York University School of Law and her B.S. in chemistry from the University of Missouri–Columbia. Kathryn is licensed to practice before the U.S. Patent and Trademark Office.